CD274 and neoplasm: This remodelling, combined with the reprogramming of tumour‐associated macrophages from an M2 to an M1 phenotype, transformed immunologically ‘cold’ tumours and markedly enhanced the efficacy of anti‐PD‐L1 therapy, achieving a 90% tumour growth inhibition rate—1.7‐fold higher than anti‐PD‐L1 therapy alone [96].